The USFDA has approved carbidopa and levodopa extended-release capsules, a new oral treatment for Parkinson's disease (PD). The drug is designed to improve the management of motor symptoms in PD patients by combining immediate-release (IR) granules with extended-release (ER) pellets, offering a longer duration of "Good On" time with less frequent dosing compared to existing IR carbidopa/levodopa (CD/LD) formulations. This innovative formulation is expected to provide significant therapeutic benefits, including a reduction in motor fluctuations and an improvement in the overall quality of life for individuals with PD.
RISE-PD clinical trial The drug has the ability to deliver 0.5 hours of additional "Good On" time per day with an average dosing frequency of three times a day, compared to five times a day with IR CD/LD. The RISE-PD clinical trial demonstrated that CD/LD offers 1.6 hours…
